Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Patent Issued - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

Patent Issued

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Kibow Biotech, Philadelphia, PA, has secured its first two U.S. patents for its scientifically validated, gut-based, uremia therapy products. Kibow is developing a probiotic and a pharmaceutical to reduce the buildup of uremic toxins in kidney disease patients. The two patents issued are U.S. No. 6,706,263 B2, titled, “Compositions for alleviating symptoms of uremia in patients” and U.S. Patent No. 6,706,287 B2, titled, “Prebiotic and Probiotic compositions and methods for their use in gut-based therapies.”

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters